ERA-EDTA BUD2019 banner 900x344 0418-1.jpg
ERA-EDTA BUD2019 banner 900x344 0418-2.jpg
ERA-EDTA BUD2019 banner 900x344 0418-3.jpg

    You are here

    • You are here:
    • Home > Scientific Programme

Scientific Programme



Diseases of emergence

Rafael Yuste, New York, NY, USA






Interface of molecular mechanisms, pathology and genetics of developmental kidney diseases

Sanjay Jain, Saint Louis, MO, USA


Single-cell transcriptomics in kidney disease

Katlin Susztak, Philadelphia, PA, USA


The pre-dialysis to renal replacement therapy transition

Csaba P. Kovesdy, Memphis, TN, USA





Late Breaking Clinical Trials


ERA-EDTA Registry


ASN Highlights

1. AKI

2. General nephrology & CKD

3. Hypertension


Nephrology pearls (Special closing session)









Phosphate and FGF23

1. FGF23 signalling in the kidney

Reinhold Erben, Vienna, Austria

2. Regulation of FGF23

Mariano Rodriguez, Cordoba, Spain

3. Phosphate toxicity in the kidney

Carsten A. Wagner, Zurich, Switzerland





Redefining the ontology of kidney diseases using genomic analysis

1. Genetic landscape of hereditary amyloidosis

2. What’s up in hereditary tubulo-interstitial nephritis?

Stanislas Kmoch, Prague, Czech Republic

3. Adult-onset ESRD of unknown aetiology: when should we think genetics?

Nine Knoers, Groningen, The Netherlands


Novel therapies in hereditary kidney diseases

1. New therapeutic targets in Alport syndrome

Roser Torra, Barcelona, Spain

2. Targeted therapies in ADPKD: what will be in the pipeline in 2020?

Ron T. Gansevoort, Groningen, Netherlands

3. Therapeutic management of cystinuria: today and tomorrow


Paediatric Nephrology

1. Childhood nephrotic syndrome: lessons from the PODONET registry

Beata S. Lipska-Ziętkiewicz, Gdańsk, Poland

2. Evidence based treatment of minimal change nephrotic syndrome: lessons from the PREDNOS trials

Nicholas Webb, Manchester, United Kingdom

3. Novel therapies for childhood minimal change nephrotic syndrome

Marina Vivarelli, Rome, Italy

4. Blood pressure in children

Kjell Tullus, London, United Kingdom



1. AKI during pregnancy: no longer an issue?

2. Lupus nephritis and pregnancy: concerns and management

3. Preventing preeclampsia





The many faces of monoclonal gammopathy of undetermined significance

1. MGRS classification: bringing order to the nomenclature chaos

Tri Nguyen, Utrecht, The Netherlands

2. MGRS diagnosis: establishing causality is the hardest job

Jolanta Malyszko, Warsaw, Poland

3. MGRS treatment: should we follow the haematologist or take the lead?


Molecular mechanisms of kidney atrophy and fibrosis

1. Diabesity-induced CKD: when kidneys get the munchies

Joseph Tam, Jerusalem, Israel

2. Does less fibrosis improve renal function? Insights from collagen I-deficiency

Matthias Mack, Regensburg, Germany

3. Pathology and mechanisms of interstitial granuloma formation

Peter Boor, Aachen, Germany


ANCA-associated vasculitis

1. Extrarenal involvement in AAV and its impact on the outcome of patients

Vladimir Tesar, Prague, Czech Republic

2. ANCA-associated vasculitis in the elderly and very elderly

Maria Weiner, Linköping, Sweden

3. Should the anti-PR3 and anti-MPO patients be treated in a different way?

4. Understanding the role of Rituximab in ANCA associated vasculitis


Lupus nephritis

1. Histologic classification of lupus nephritis – time for a change?

Ingeborg M. Bajema, Leiden, Netherlands

2. Pathogenesis of SLE and systemic lupus nephritis – what is new?

Hans-Joachim Anders, Munich, Germany

3. Biologic therapy in lupus nephritis – where are we now?


Primary glomerulonephritides

1. THSD7A antibody induced disease - pathophysiology and clinical patterns

Rolf A.K. Stahl, Hamburg, Germany

2. Spontaneous remission in membranous nephropathy – how long should we wait?

Fernando Fervenza, Rochester, MN, USA

3. Serology-based algorithm of the treatment of membranous nephropathy

4. What is the optimal approach to the treatment of IgA nephropathy in 2019?

Jürgen Floege, Aachen, Germany





The many facets of hypoxia in CKD

1. Hypoxia and CKD progression

2. Sleep disordered breathing: a pervasive problem in CKD

Francesca Mallamaci, Reggio Calabria, Italy

3. Intradialysis hypoxia

Peter Kotanko, New York, NY, USA

4. Chronic interstitial nephritis of unknown etiology is a toxic tubular nephropathy

Marc de Broe, Antwerp, Belgium


Neuroinflammation and CKD

1. The gut-brain axis, b2microglobulin and neuroinflammation: a re-interpretation of an old story?

Michel Jadoul, Brussels, Belgium

2. Anti-inflammatory role of the parasympathetic system in CKD

Annette Bruchfeld, Stockholm, Sweden

3. Neuroinflammation and hypertension


The role of diet in the prevention of CKD progression: food for thought

1. Kidney disease and the westernization and industrialization of food

2. Dietary protein restriction: PRO

Denis Fouque, Lyon, France

3. Dietary protein restriction: AGAINST

Marc Vervloet, Amsterdam, Netherlands

4. Sodium as a regulator of immunity


The gut-kidney-cardiovascular axis

1. Gut microbiota and microbial metabolism in CKD across stages of diseases

Griet Glorieux, Ghent, Belgium

2. Gut dysbiosis and thrombosis

3. Gut dysbiosis and vascular calcification

Ziad Massy, Paris, France

4. Role of dietary potassium in natriuresis, blood pressure, and cardio-renal outcomes


The paradox of estimated GFR in the era of precision medicine

1. Overview of the error of creatinine and cystatin-c-based formulas in clinical practice

Esteban Porrini, La Laguna, Spain

2. Measured GFR in clinical practice, the Swedish experience

Anders Christensson, Malmö, Sweden

3. Which method to measure GFR and in which clinical conditions?

Pierre Delanaye, Liège, Belgium

4. MRI approaches to asses kidney injury and function

Faikah Güler, Hannover, Germany


New insights in molecular mechanism of cardiovascular diseases in CKD

1. Oxidative stress on myocardial function in CKD

Leticia Prates Roma, Homburg/Saar, Germany

2. Lipoproteins in CKD-associated vascular diseases

Thimoteus Speer, Homburg/Saar, Germany

3. Atherosclerosis, cardiac remodelling and CKD

Heidi Noels, Aachen, Germany





Haemodialysis. From incremental approaches to frequent treatments

1. The concept of incremental haemodialysis

Carlo Basile, Acquaviva delle Fonti, Italy

2. Clinical experiences with incremental haemodialysis schedules

Kamyar Kalantar-Zadeh, Orange, CA, USA

3. Assuring adequate preparation and choice for advanced CKD patients facing kidney failure (CKDopps)


Controversy: does haemodiafiltration improve patient outcomes and survival?

1. No

Francesco Locatelli, Lecco, Italy

2. Yes

Peter J. Blankestijn, Utrecht, Netherlands

3. Increasing convection: what happens to the different uraemic toxins when increasing convection in post-dilutional HDF?

Angel Argiles Ciscart, Montpellier, France


Start dialysis? Stop dialysis? - Challenging conversations

1. Dialysis or conservative care?

Wim Van Biesen, Ghent, Belgium

2. Is this the time to consider dialysis withdrawal?

Monika Lichodziejewska-Niemierko, Gdańsk, Poland

3. Different conversations for different ethnic groups?

Edwina Brown, London, United Kingdom

4. Clinical Practice Guideline on management of older patients with advanced chronic kidney disease

Adrian Covic, Iași, Romania


Delivering good quality dialysis - what should we measure?

1. Small solute clearance: what are the pitfalls?

2. Patient-reported outcomes: are these fit for purpose?

Ken Farrington, Stevenage, United Kingdom

3. Towards a multidimensional measure of dialysis adequacy?


The hidden risks of haemodialysis

1. Silent ischemia during haemodialysis

Christopher W McIntyre, London, Canada

2. Haemodynamic instability and ischemic brain injury

Adrian Covic, Iași, Romania

3. Tolerability of extracorporeal treatments in 2019

4. Clinical Practice Guideline on Vascular Access

Maria Haller, Linz, Austria


CKD-MBD patterns and therapeutic approaches: update 2019

1. Klotho, a new player coming to age

Marc Vervloet, Amsterdam, Netherlands

2. New insights in pathogenesis and treatment of vascular calcification

Catherine Shanahan, London, United Kingdom

3. Osteoporosis in CKD, a diagnostic and therapeutic challenge on the move





Optimizing peritoneal dialysis prescription

1. Why testing peritoneal membrane characteristics?

Johann Morelle, Brussels, Belgium

2. Optimizing PD initiation and reducing early switches to HD: Insights from PDOPPS

Simon Davies, Stoke-on-Trent, United Kingdom

3. Individualising prescription for residual renal function


Home haemodialysis: on the move

1. Reducing the costs of end stage renal disease while delivering quality health care: are home therapies the answer?

Wim Van Biesen, Ghent, Belgium

2. Striving to achieve an integrated home dialysis system

3. Vascular access in HHD: the Achilles tendon?

Sandip Mitra, Manchester, United Kingdom


Frail elderly: management best at home

1. Integrating geriatric assessment into routine dialysis care

Edwina Brown, London, United Kingdom

3. Integrating with community geriatric services

4. Addressing potentially inappropriate medications in older adults with kidney disease





Overcoming age with frailty evaluation in the kidney transplant recipient

1. Are frailty and sarcopenia definitions precise enough to establish a clinical diagnosis in the patient with chronic disease?

Juan Jesus Carrero, Stockholm, Sweden

2. The best frailty evaluation before kidney transplantation

3. Outcomes of frail patients after kidney transplantation

Maria José Pérez-Sáez, Barcelona, Spain


Precision medicine for the sensitized transplant recipient

1. Tailoring a transplant route for the sensitized patient on dialysis

Marta Crespo, Barcelona, Spain

2. Taking care: balancing immunosuppression avoiding weapons of mass destruction

Julio Pascual, Barcelona, Spain

3. Obesity in transplantation


Basic immunology and pathology

1. Necroinflammation in kidney transplantation

2. Polyoma nephropathy

Jan Ulrich Becker, Cologne, Germany

3. Banff update

Carmen Lefaucheur, Paris, France


Improving the organ donor pool

1. Controlled Cardiac Donor Death program in Spain: one vision for the future

Beatriz Dominguez Gil, Madrid, Spain

2. Kidney protection in living donors

Charles Ferro, Birmingham, United Kingdom

3. Compatibility barriers/Increasing the pool of marginal donors





Improving outcomes in DKD

1. Renal inflammation: its pathogenetic role in diabetic kidney disease

Sydney Tang, Hong Kong, Hong Kong

2. Basic science: SGLT2 inhibitors in the prevention of renal fibrosis

3. Update on SGLT2i in CKD

Christoph Wanner, Würzburg, Germany

4. GLP-1 receptor agonists in DKD: mechanisms and outcomes

Johannes F.E. Mann, Munich, Germany


Salt and disease: a changing scenario / Sodium: where is it? How does it harm? How could we intervene?

1. Salt and hypertension: a bacterial affair

Nicola Wilck, Berlin, Germany

2. Tissue sodium storage in end stage kidney disease

Anke Dahlmann, Erlangen, Germany

3. Gender and renal salt handling

4. Renal potassium sensing and control of sodium balance

Johannes Loffing, Zurich, Switzerland


Cardiovascular disease in CKD: risk factors and remedies

1. Why is the risk of stroke so high in CKD and in dialysis patients?

Sydney Tang, Hong Kong, Hong Kong

2. Clinical trials and research priorities in dialysis patients

Csaba P. Kovesdy, Memphis, TN, USA

3. Modifiable risk factors for cardiovascular disease in CKD: a hierarchical approach

Rajiv Agarwal, Indianapolis, IN, USA

4. China Kidney Network (CK-NET): Opportunities for Kidney Disease in the Era of Big Data


Digging the aetiology of hypertension

1. Biological insights from GWAS

2. Thrombotic microangiopathy and malignant hypertension

Jean-Michel Halimi, Tours, France

3. Insights from adverse effects of drugs

Petra Tesarova, Prague, Czech Republic

4. Out-of-office BP monitoring and BP variability in chronic kidney disease: current concepts and future directions

Pantelis Sarafidis, Thessaloniki, Greece


Blood pressure targets

1. Optimal BP target for renoprotection in CKD patients is <140/90

Mustafa Arici, Ankara, Turkey

2. Optimal BP target for renoprotection in CKD patients is <130/80

Pantelis Sarafidis, Thessaloniki, Greece

3. Managing resistant hypertension

Andrzej J. Wiecek, Katowice, Poland

4. Endothelin receptors, natriureis, kidney disease and hypertension





AKI: current problems in clinical practice

1. To fill or not to fill: what is the evidence

2. Heart failure and AKI

Stephan von Haehling, Gottingen, Germany

3. Genetic susceptibility and AKI

Michael Heung, Ann Arbor, USA

4. References to urinary tract disease in the Works of Thomas of Wroclaw (1297-1378), the Continuator of Arnaldo de Villanova's Medical Thought

Janusz Ostrowski, Warsaw, Poland


Renal Replacement Therapy in the Intensive Care Unit

1. Modality and dose: where do we stand?

2. When to start dialysis: the final answer?

Julien Maizel, Amiens, France

3. The intertwined relation between CKD and AKI: pitfalls and cobblestones






Renal and intestinal oxalate transport, inflammation and CKD

Felix Knauf, Berlin, Germany


Autophagy in kidney diseases

Yoshitaka Isaka, Suita, Japan


Interallelic interactions of podocin

Kálmán Tory, Budapest, Hungary


Personalised diagnosis and CKD prediction in genetic tubular disorders

Francesca Becherucci, Florence, Italy


Whole-exome sequencing in adults with CKD


New therapies in the Henoch-Schönlein syndrome

Roberta Fenoglio, Turin, Italy


Role of complement in the pathogenesis and progression of IgA nephropathy

Rosanna Coppo, Turin, Italy


IgA Nephropathy: Evidences from China


PCSK9 in kidney disease

Danilo Fliser, Homburg/Saar, Germany


From human embryonic nephron stem cells to mature kidney tissue and regeneration

Benjamin Dekel, Ramat Gan, Israel


Kidney regeneration using induced pluripotent stem (iPS) cells

Takashi Yokoo, Tokyo, Japan



Vincent Brandenburg, Aachen, Germany


The Swedish Health databases; an abundance of possibilities for kidney research

Juan Jesus Carrero, Stockholm, Sweden


When should a nephrologist take over – stage 3b or 4 – current perspective

Goce Spasovski, Skopje, F.Y.R. of Macedonia


“Doctor: how long may I live in dialysis”?

Jürgen Floege, Aachen, Germany


Is there room to improve dialysis stability? Should we change time, dialysis modality, dialysate solute concentrations, dialysate temperature, all of them or nothing of it?


How to measure residual renal function

Andrew Davenport, London, United Kingdom


New approaches to enhance removal, particularly of protein bound solutes

Joachim Jankowski, Aachen, Germany


The global fluid study


Self-care improves patient outcomes: what is the evidence?

Martin Wilkie, Sheffield, United Kingdom


Molecular targets in renal transplantation: reality or fiction?

Michael Mengel, Edmonton, Canada


TRANSFORM, the largest trial ever done in transplantation: lessons after 3 years

Julio Pascual, Barcelona, Spain


Vitamin D after kidney transplantation

Markus Ketteler, Coburg, Germany


Vascular calcification and Iron metabolism – are they connected?

József Balla, Debrecen, Hungary


Bariatric surgery: untangling the links between diabetes, hypertension and kidney disease?

Anna Solini, Pisa, Italy


The overdriven glomerulus as a CV risk factor

Francesca Mallamaci, Reggio Calabria, Italy


Diabetic kidney disease in Asia: a growing threat


Clinical Practice Guideline on management of patients with diabetes and advanced chronic kidney disease

Maria Jose Soler Romeo, Barcelona, Spain


AKI in hospital: risk factors and strategies for prevention


Prevention of AKI in oncology


Omics in AKI diagnosis






Primary and Secondary Glomerulonephritis, vasculitis and auto-immune diseases

1. Minimal change disease and FSGS

Jack Wetzels, Nijmegen, Netherlands

2. Membranous Nephropathy

3. IgA Nephropathy

Rosanna Coppo, Turin, Italy

4. New directions in the treatment of ANCA-associated nephritis

Marten Segelmark, Lund, Sweden

5. Lupus Nephritis

Vladimir Tesar, Prague, Czech Republic



1. Concept and global burden of CKD: current status and beyond

Ron Gansevoort, Groningen, Netherlands

2. What is the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+)?

Marie Evans, Stockholm, Sweden

2. What's new about acute on chronic kidney disease?

4. Anaemia management in CKD patients: past, present and the future

5. Optimal timing and method for RRT proposed to CKD patients

Raymond Vanholder, Ghent, Belgium


Hypertension, Diabetes and CV Disease in CKD

1. Inflammation in CKD: cures at last?

Danilo Fliser, Homburg/Saar, Germany

2. Progress in the prevention and cure of diabetic nephropathy

3. Prognosis by risk calculators in CKD and in ESRD

Friedo W. Dekker, Leiden, Netherlands

4. LV dysfunction with preserved Ejection Fraction in CKD: epidemiology, mechanism(s) and therapy


Bone Mineral disorders in CKD

1. How to prevent fractures in CKD?

Pieter Evenepoel, Leuven, Belgium

2. Are we inducing adynamic bone disease, and is that a problem?

Mathias Haarhaus, Stockholm, Sweden

3. Is FGF23 outdated?

Marc Vervloet, Amsterdam, Netherlands

4. Don’t forget our old friend Vitamin D, which could include the position of novel formulation of non-active vitamin D


Genetic Diseases and Rare Diseases

1. Genomic studies in monogenic and kidney stone disease

Jan Halbritter, Leipzig, Germany

2. Genomic studies in adult CKD patients

Ali G. Gharavi, New York, NY, USA

3. Recent GWAS of kidney function markers

Anna Koettgen, Freiburg, Germany

4. Polycystic kidney disease: new genes and clinical studies

Olivier Devuyst, Zürich, Switzerland

5. Update on tubular and tubulointerstitial diseases

Detlef Bockenhauer, London, United Kingdom


Basic and Transitional Nephrology

1. Kidney diseases at single cell level

Rafael Kramann, Aachen, Germany

2. The new age of kidney imaging

Nicole Endlich, Greifswald, Germany

3. New models of kidney development and regeneration

4. How we survive acute injury and develop chronic disease: kidney, heart and liver not so different after all

Paola Romagnani, Florence, Italy

5. Optogenetic control of inflammation in acute kidney injury

Mark D. Okusa, Charlottesville, VA, USA



1. Renal Biopsy: pitfalls

2. FSGS on renal biopsy: why an integrated approach to diagnosis is necessary

Laura Barisoni, Durham, NC, USA

3. Atypical post-streptococcal GN and complement

4. Diabetic Nephropathy versus Kidney Diseases in Diabetics

Loreto Gesualdo, Bari, Italy

5. The histopathologic spectrum of obesity-related glomerulopathy

Helen Liapis, Little Rock, AR, USA

6. Update on fibrillary and immunotactoid glomerulopathy

Sándor Turkevi-Nagy, Szeged, Hungary

7. Renal side effects of novel anti-cancer drugs

Joris Roelofs, Amsterdam, Netherlands

8. Tubulointerstitial infiltrates in glomerular diseases

9. How to diagnose chronic TCMR in kidney transplants: Banff and the evidence

Marion Rabant, Paris, France


Haemodialysis and Vascular Access

Vascular access

1. Prevention and treatment of central venous catheter infections

Laura Labriola, Brussels, Belgium

2. New developments in vascular access, what can we expect for the future? Maturation, thrombosis prevention etc.

Joris Rotmans, Leiden, Netherlands

3. Recent guidelines on vascular access: ERBP, KDIGO, Eur Soc Vasc Surg,

Evi Nagler, Ghent, Belgium


1. Dialysis care: personalized or universal? (Focus on PROMs, so discuss SONG, ICHOM, etc. and how to implement this in daily care?)

Andrew Davenport, London, United Kingdom

2. HDF in children: what can we learn from paediatric studies

Rukshana Shroff, London, United Kingdom

3. How to increase home and self-care haemodialysis?

Sandip Mitra, Manchester, United Kingdom


Renal Transplantation

1. Can this person receive a kidney: what is the minimal workup that should be done in a healthy kidney transplant candidate?

Luuk Hilbrands, Nijmegen, Netherlands

2. How long this patient with previous cancer should wait before being wait-listed?

Bruno Watschinger, Vienna, Austria

3. How can I evaluate this extended criteria kidney according to ECD, DCD, KDRI?

Umberto Maggiore, Parma, Italy

4. How should I prevent CMV disease and BK PVN in 2019?

5. How should I personalise maintenance therapy according to donor/recipient factors?

Klemens Budde, Berlin, Germany



1. Volume management throughout the course of AKI: Risk – Oliguria – RRT – Polyuria

Wim Van Biesen, Ghent, Belgium

2. AKI in geriatric population and in frailty

Norbert Lameire, Ghent, Belgium

3. AKI in austere environments

Valerie A. Luyckx, Zürich, Switzerland

4. Biopsy in AKI: WHEN and WHY?: Indicated / non-indicated / contraindicated?

5. Recent clinical trials and update in AKI

Andreas Kribben, Essen, Germany


Peritoneal Dialysis

1. PD catheter insertion and complications

Victoria R. Briggs, Sheffield, United Kingdom

2. How to prescribe APD

Carl M. Öberg, Lund, Sweden

3. Prevention, diagnostics and treatment of peritonitis

Anabela Rodrigues, Porto, Portugal

4. Update on PD solutions

Monika Lichodziejewska-Niemierko, Gdańsk, Poland

5. Changes in peritoneal structure and function with time on PD

Johann Morelle, Brussels, Belgium


Electrolytes and urolithiasis

1. Disorders of sodium and water

Ewout Hoorn, Rotterdam, Netherlands

2. Hypo- and Hyperkalemia

Felix Knauf, Berlin, Germany

3. Disorders of calcium and magnesium

Pascal Houillier, Paris, France

4. Acid-Base disturbances and stones (case-based)

5. Stones and electrolytes (case-based)

Philippe Jaeger, London, United Kingdom


ERA-EDTA Registry

1. Different flavours in RCTs and their analyses

Giovanni Luigi Tripepi, Reggio Calabria, Italy

2. Pros and cons of surrogate outcomes in RCTs

Kitty Jager, Amsterdam, Netherlands

3. Mendelian randomization to enable causal inference in observational studies

Friedo W. Dekker, Leiden, Netherlands

4. Directed acyclic graphs (DAGs) to address confounding

Natalie Staplin, Oxford, United Kingdom

5. The health economic toolbox in nephrology




From the distant past to the sunny future





Session 1

Can we talk about regional common fate in Nephrology?

1. The European perspective (epidemiology)

2. The role of supranational – regional societies

3. Epidemiology and economics

Orsolya Cseprekál, Budapest, Hungary

4. Special issues of AKI and CKD in medium income regions

Mehmet Sukru Sever, Istanbul, Turkey


Session 2

From the molecule to social determinism. Challenges in Nephrology

1. Translational medicine and real life

Anupan Agarwal, Birmingham, AL, USA

2. The arteriosclerosis epidemic in CKD

Rukshana Shroff, London, UK

3. Choice of dialysis modality pediatrics vs adults

4. Transplantation

Ondrej Viklicky, Prague, Czech Republic

5. Psycho-nephrology


Session 3

The roots of adult diseases go back to childhood

1. The role of prematurity in kidney diseases in children and adults

Attila Szabo, Budapest, Hungary

2. Adolescent hypertension: transition from the adolescent to the adult

3. Cardiovascular consequences of paediatric CKD

4. Diabetes - the changing face of a disease

5. Progression of kidney disease in childhood


Session 4

Nephrology: The Hungarian Perspective

1. From Koranyi to WKD - Reestablishment of a European Center

László Rosivall, Budapest, Hungary

2. From RAS to renal tissue repair - visualization of physiology and pathophysiology

Janos Peti-Peterdi, Los Angeles, CA, USA

3. Non-traditional risk factors of kidney transplant recipients: pieces from a big Hungarian study

Miklos Molnar, Memphis, TN, USA

4. New challenges in kidney transplantation: machine perfusion